BioAge Labs, Inc. (BIOA) Stock Statistics & Valuation Metrics

BioAge Labs, Inc. has a market cap or net worth of $1.12B. The enterprise value is $514.87M.

BioAge Labs, Inc. has 44,452,736 shares outstanding. The number of shares has decreased by -2.65% in one year.

BioAge Labs, Inc.’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.38%.

The current PE Ratio of BioAge Labs, Inc. is ―. BioAge Labs, Inc.’s PEG ratio is -0.45.

In the last 12 months, BioAge Labs, Inc. had revenue of 8.99M and earned -80.61M in profits. Earnings per share was -2.24.

In the last 12 months, operating cash flow was -88.31M and capital expenditures -319.00K, giving a free cash flow of -88.63M billion.

BioAge Labs, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

BioAge Labs, Inc. upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

BioAge Labs, Inc. as a current ratio of 14.24, with Debt / Equity ratio of 1.06%

In the past 12 months, BioAge Labs, Inc. has paid 0.00 in taxes.

BioAge Labs, Inc. EV to EBITDA ratio is -3.66, with an EV/FCF ratio of -3.55.

BioAge Labs, Inc. has $383.19M in cash and marketable securities with $4.03M in debt, giving a net cash position of $379.16M billion.

Gross margin is 99.39%, with operating margin of -1031.46%, and net profit margin of -896.11%.

The average price target for BioAge Labs, Inc. is $37.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy